Literature DB >> 29076047

Tetracycline use in the community may promote decreased susceptibility to quinolones in Escherichia coli isolates.

E Batard1,2, M-A Vibet3, S Thibaut4, S Corvec5, J Pivette6, D Lepelletier7,5, J Caillon4,5, E Montassier7,8.   

Abstract

We previously found that the hospital use of tetracyclines is associated with quinolone resistance in hospital isolates of Enterobacteriaceae. Tetracyclines are heavily used in the community. Our aim was to assess whether their use in the community favors quinolone resistance in community isolates of Escherichia coli. Monthly data of community antibiotics use and E. coli quinolone resistance in a 1.3 million inhabitant French area were obtained from 2009 to 2014, and were analyzed with autoregressive integrated moving average (ARIMA) models. Quinolone use decreased from 10.1% of the total antibiotic use in 2009 to 9.3% in 2014 (trend, - 0.016; p-value < 0.0001), while tetracycline use increased from 16.5% in 2009 to 17.1% in 2014 (trend, 0.016; p < 0.0001). The mean (95% confidence interval) monthly proportions of isolates that were non-susceptible to nalidixic acid and ciprofloxacin were 14.8% (14.2%-15.5%) and 9.5% (8.8%-10.1%), respectively, with no significant temporal trend. After adjusting on quinolone use, tetracycline use in the preceding month was significantly associated with nalidixic acid non-susceptibility (estimate [SD], 0.01 [0.007]; p-value, 0.04), but not with ciprofloxacin non-susceptibility (estimate [SD], 0.01 [0.009]; p-value, 0.23). Tetracycline use in the community may promote quinolone non-susceptibility in E. coli. Decreasing both tetracycline and quinolone use may be necessary to fight against the worldwide growth of quinolone resistance.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29076047     DOI: 10.1007/s10096-017-3127-0

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  23 in total

1.  High prevalence of cross-resistance to fluoroquinolone and cotrimoxazole in tetracycline-resistant Escherichia coli human clinical isolates.

Authors:  Eric Batard; Mathilde Lefebvre; Guillaume Ghislain Aubin; Nathalie Caroff; Stéphane Corvec
Journal:  J Chemother       Date:  2016-05-27       Impact factor: 1.714

2.  Epidemiology of third-generation cephalosporin-resistant community-acquired Enterobacteria isolated from elderly patients.

Authors:  S Thibaut; J Caillon; A Marquet; G Grandjean; G Potel; F Ballereau
Journal:  Med Mal Infect       Date:  2014-02-18       Impact factor: 2.152

3.  Bacteriological examination of rectal specimen during long-term oxytetracycline treatment for acne vulgaris.

Authors:  H Schmidt; E From; G Heydenreich
Journal:  Acta Derm Venereol       Date:  1973       Impact factor: 4.437

4.  R Factors in Escherichia coli in faeces after oral chemotherapy in general practice.

Authors:  N Datta; M C Faiers; D S Reeves; W Brumfitt; F Orskov; I Orskov
Journal:  Lancet       Date:  1971-02-13       Impact factor: 79.321

5.  Sequential antibiotic therapy for acne promotes the carriage of resistant staphylococci on the skin of contacts.

Authors:  Y W Miller; E A Eady; R W Lacey; J H Cove; D N Joanes; W J Cunliffe
Journal:  J Antimicrob Chemother       Date:  1996-11       Impact factor: 5.790

6.  Susceptibility to the main antibiotics of Escherichia coli and Staphylococcus aureus strains identified in community acquired infections in France (MedQual, 2004-2007).

Authors:  S Thibaut; J Caillon; C Huart; G Grandjean; P Lombrail; G Potel; F Ballereau
Journal:  Med Mal Infect       Date:  2009-10-17       Impact factor: 2.152

7.  Duration of oral tetracycline-class antibiotic therapy and use of topical retinoids for the treatment of acne among general practitioners (GP): A retrospective cohort study.

Authors:  John S Barbieri; Ole Hoffstad; David J Margolis
Journal:  J Am Acad Dermatol       Date:  2016-08-05       Impact factor: 11.527

8.  Long-term antibiotic therapy for acne vulgaris: effects on the bowel flora of patients and their relatives.

Authors:  S J Adams; W J Cunliffe; E M Cooke
Journal:  J Invest Dermatol       Date:  1985-07       Impact factor: 8.551

9.  Non-hospital antimicrobial usage and resistance in community-acquired Escherichia coli urinary tract infection.

Authors:  G Kahlmeter; P Menday; O Cars
Journal:  J Antimicrob Chemother       Date:  2003-11-12       Impact factor: 5.790

10.  Relationship between hospital antibiotic use and quinolone resistance in Escherichia coli.

Authors:  Eric Batard; Florence Ollivier; David Boutoille; Jean-Benoît Hardouin; Emmanuel Montassier; Jocelyne Caillon; Françoise Ballereau
Journal:  Int J Infect Dis       Date:  2012-11-22       Impact factor: 3.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.